Podcasts about washington university school

Once the most popular graft choice for ACL reconstruction surgery, hamstring autograft has recently fallen out of favor for a variety of concerns including a higher graft rupture rate in younger athletes and concerns over graft diameters that tend to run smaller. However, what does the best level evidence actually say about hamstring autograft's long-term performance versus the current gold-standard, patellar tendon autograft? Dr. Derrick Knapick, MD joins us from Washington University School of Medicine in St. Louis to discuss his study looking at this question.    

In the third edition of a special podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about optimal strategies for incorporating different therapeutic agents into lung cancer care. As part of the latest discussion, the group highlighted the relevant efficacy data, administration protocols, and toxicity management considerations associated with TROP2-directed antibody-drug conjugates (ADCs) in patients with non–small cell lung cancer (NSCLC). Morgensztern is a professor of Medicine and the clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital. Morgensztern opened the discussion by highlighting the characteristics of prominent TROP2-targeting ADCs in NSCLC management, which included sacituzumab govitecan-hziy (Trodelvy), datopotamab deruxtecan-dlnk (Datroway), and sacituzumab tirumotecan (sac-TMT). Additionally, he reviewed data from clinical trials assessing these ADCs across different NSCLC populations, including the phase 3 EVOKE-01 trial (NCT05089734) showing a numerical overall survival (OS) improvement with sacituzumab govitecan vs docetaxel. Regarding the safety profiles of these ADCs, Flanagan described the unique toxicities associated with the agents' payloads as well as potential off-target effects. On top of myelosuppression, fatigue, and diarrhea, she stated that these therapies may cause more visceral organ toxicities like keratitis of the eye and interstitial lung disease. According to Flanagan, some prophylactic measures in the event of certain toxicities include frequent salt and baking soda mouth rinses as well as oral dexamethasone.  Mann then outlined the dosing variability considerations and supportive care measures surrounding the use of agents like sacituzumab govitecan. She emphasized continuously re-educating patients about expected toxicities and supportive care strategies as they undergo these infusion-based therapies to help avoid surprise instances of ocular toxicity, diarrhea, and other adverse effects. Reference Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42(24):2860-2872. doi:10.1200/JCO.24.00733

Dr Isaac Amon shares how his diverse Sephardi, Mizrachi, and Ashkenazi heritage have shaped his sense of identity. From Istanbul to the American Midwest, Isaac reflects on how his family's stories, languages, food, and community influence his connection to Jewish life. Our GuestDr. Isaac Amon is an attorney and counselor at law, Adjunct Professor at Washington University School of Law in St. Louis, and Director of Academic Research at Jewish Heritage Alliance, an educational platform dedicated to promoting the legacy of Sefarad, or Iberian Jewry. Isaac is also Director of Academic Research at the Jewish Heritage Alliance, which aims to preserve and share the history of Sephardi and Mizrachi Jews. Key TopicsNavigating Identity: How Isaac's family history blends diverse Jewish roots, creating a rich but often challenging sense of belonging.Language and Culture: The role of multilingualism within Isaac's family and how language shapes identityChallenging Normativity: The experience of living as a Sephardi Jew in predominantly Ashkenazi spaces and the ongoing struggle for inclusionYour guideShort definitions of terms mentioned in this episode:Ladino: A Judeo-Spanish language spoken by Sephardi Jews.Kaddish: A prayer recited in memory of the dead, with variations between communities.Burekas: Savory pastries filled with cheese, spinach, or potatoes, common in Sephardi and Mizrachi Jewish cuisines.Shakshuka: A dish of poached eggs in a spicy tomato and pepper sauce, popular in Sephardi and Mizrachi cultures.Passover Brown Eggs: Eggs boiled in onion skins, a Sephardi Passover tradition.Want to learn more? Listen to previous episodes where we discuss identity.S2E1: Discussing diverse Jewish national identities with Yaacov Yadgar S1E7: Languages and Identities challenged by Ophira GamlielReferences & ResourcesJewish Heritage Alliance - An organisation preserving and promoting Sephardi and Mizrachi Jewish historyARTICLE “Five-Hundred Years in the Life of the Amon Family: From the surrender of Spain to the court of Suleiman the Magnificent and beyond, they were there” – Published, National Library of Israel Blog, December 2020VIDEO: “Crossroads of Sefarad: In the Footsteps of the Crypto-Jews,” created jointly by Jewish Heritage Alliance and ANU Museum of the Jewish PeopleFind us elsewhere, here!Show creditsHost / Producer: Eylan EzekielPost-production: Communicating for ImpactArtwork: Emily TheodoreMusic: Aleksafor utransndr KarabanovSound effects: Serge Quadrado Hosted on Acast. See acast.com/privacy for more information.

Ahead of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with a variety of oncology experts about the late-breaking abstracts, plenary sessions, and other key presentations that may shift the paradigm across different cancer care fields. They highlighted anticipated clinical trial results that may transform the standard of care for gynecologic malignancies, lung cancer, and other disease types. Rachel N. Grisham, MD, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at MSK Westchester of Memorial Sloan Kettering Cancer Center, shared her anticipation of findings from the phase 3 ROSELLA trial (NCT05257408) assessing relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. She stated she was excited to see if the data may represent a new opportunity for this patient population. Next, MinhTri Nguyen, MD, a medical oncologist and hematologist at Stanford Health Care, highlighted a few breast cancer presentations to look out for. These topics included a plenary session on data from the phase 3 SERENA-6 study (NCT04964934) evaluating camizestrant in combination with CDK4/6 inhibitors for those with hormone receptor–positive, HER2-negative advanced breast cancer harboring emergent ESR1 mutations. Additionally, Eric K. Singhi, MD, assistant professor in the Department of General Oncology in the Division of Cancer Medicine, and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, spoke about a range of potentially practice-changing results in the lung cancer field. For example, he described a session focused on primary results of the phase 3 IMforte trial (NCT05091567) assessing lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) for those with extensive-stage small cell lung cancer (ES-SCLC). According to Singhi, data from IMforte may shift the paradigm of maintenance therapy for this SCLC population. In the world of head and neck cancer, Douglas R. Adkins, MD, associate professor of Internal Medicine, Division of Oncology, Section of Medical Oncology at Washington University School of Medicine in St. Louis, Missouri, highlighted the session on the phase 3 NIVOPOSTOP GORTEC 2018-01 trial (NCT03576417). Investigators of this study evaluated nivolumab (Opdivo) in combination with chemoradiotherapy for those with resected head and neck squamous cell carcinoma. Adkins noted his excitement to see how these data may impact the standard of care, particularly for patients in Europe, where investigators conducted the study. As part of an Oncology Decoded discussion, Benjamin Garmezy, MD, the associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, discussed key abstracts in bladder cancer. One specific presentation included additional findings from the phase 3 NIAGARA trial (NCT03732677), which may show how circulating tumor DNA can influence treatment decision-making regarding perioperative durvalumab (Imfinzi) for patients with muscle-invasive bladder cancer.

Dr. Christopher Ray is a vascular neurologist at Washington University School of Medicine. He joins KMOX Health Editor Fred Bodimer with details on a new study focusing on acute migraines. Photo by Alamy/PA Images/Alamy Images/Sipa USA)

President Trump says the U.S. government is poised to accept an airplane from Qatar valued at nearly $400 million. He claims the 747 aircraft will replace the 40-year-old Air Force One. But the announcement has raised ethical and national security concerns. Geoff Bennett discussed more with Kathleen Clark, a government ethics expert and professor at Washington University School of Law. PBS News is supported by - https://www.pbs.org/newshour/about/funders

President Trump says the U.S. government is poised to accept an airplane from Qatar valued at nearly $400 million. He claims the 747 aircraft will replace the 40-year-old Air Force One. But the announcement has raised ethical and national security concerns. Geoff Bennett discussed more with Kathleen Clark, a government ethics expert and professor at Washington University School of Law. PBS News is supported by - https://www.pbs.org/newshour/about/funders

Research from Professor Rumi Kato Price at the Washington University School of Medicine and her colleagues, Professors Sheldon Zhang and Annah Bender, reveals how research-driven, standardized indicator approaches can better identify human trafficking victims than traditional legal and prosecutorial frameworks. Their work in Cape Town, South Africa demonstrates that trafficking victimization exists on a spectrum rather than as a binary classification, with implications for improving identification and support for victims worldwide.

Since American president Donald Trump was elected to a second term, it is common to hear citizens, journalists, and public officials distinguish between the laws and leaders of their states and the national government. Those who oppose Trump's policies with regard to reproductive rights, gun violence, LGBTQ+, education, police, and voting often present state constitutions, courts, laws, culture, and leaders as a bulwark against Trump's autocratic rule.  But Professor Stephen H. Legomsky sees it differently. His new book, Reimagining the American Union: The Case for Abolishing State Government (Cambridge University Press 2025) argues that – if we care about democracy – we should imagine an America without state government. No longer a union of arbitrarily constructed states, the country would become a union of one American people. Reimagining the American Union understands state government as the root cause of the gravest threats to American democracy. While some of those threats are baked into the Constitution, the book argues that others are the product of state legislatures abusing their powers through gerrymanders, voter suppression, and other less-publicized manipulations that often target African-Americans and other minority voters. Reimagining the American Union interrogates how having national, state and local legislative bodies, taxation, bureaucracy, and regulation wastes taxpayer money and burdens the citizenry. After assessing the supposed benefits of state government, Professor Legomsky argues for a new, unitary American republic with only national and local governments. Stephen H. Legomsky is the John S. Lehmann University Professor Emeritus at the Washington University School of Law. Professor Legomsky has published scholarly books on immigration and refugee law, courts, and constitutional law. He served in the Obama Administration as Chief Counsel of U.S. Citizenship and Immigration Services and later as Senior Counselor to Secretary of Homeland Security Jeh Johnson. He was a member of President-Elect Biden's transition team, has testified often before Congress, and has worked with state, local, UN, and foreign governments. Mentioned: Cambridge University press is offering a 20% discount here (until October) Susan's NBN interview with Richard Kreitner on Break It Up: Secession, Division, and The Secret History of America's Imperfect Union Jonathan A. Rodden's Why Cities Lose: The Deep Roots of the Urban-Rural Political Divide (Basic Books 2019) Hendrik Hertzberg's review of Robert A. Dahl's How Democratic Is the American Constitution (Yale) Shelby County v. Holder, the Supreme Court case that overturned the Voting Rights Act of 1965's pre-clearance requirement for historically discriminating districts Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Since American president Donald Trump was elected to a second term, it is common to hear citizens, journalists, and public officials distinguish between the laws and leaders of their states and the national government. Those who oppose Trump's policies with regard to reproductive rights, gun violence, LGBTQ+, education, police, and voting often present state constitutions, courts, laws, culture, and leaders as a bulwark against Trump's autocratic rule.  But Professor Stephen H. Legomsky sees it differently. His new book, Reimagining the American Union: The Case for Abolishing State Government (Cambridge University Press 2025) argues that – if we care about democracy – we should imagine an America without state government. No longer a union of arbitrarily constructed states, the country would become a union of one American people. Reimagining the American Union understands state government as the root cause of the gravest threats to American democracy. While some of those threats are baked into the Constitution, the book argues that others are the product of state legislatures abusing their powers through gerrymanders, voter suppression, and other less-publicized manipulations that often target African-Americans and other minority voters. Reimagining the American Union interrogates how having national, state and local legislative bodies, taxation, bureaucracy, and regulation wastes taxpayer money and burdens the citizenry. After assessing the supposed benefits of state government, Professor Legomsky argues for a new, unitary American republic with only national and local governments. Stephen H. Legomsky is the John S. Lehmann University Professor Emeritus at the Washington University School of Law. Professor Legomsky has published scholarly books on immigration and refugee law, courts, and constitutional law. He served in the Obama Administration as Chief Counsel of U.S. Citizenship and Immigration Services and later as Senior Counselor to Secretary of Homeland Security Jeh Johnson. He was a member of President-Elect Biden's transition team, has testified often before Congress, and has worked with state, local, UN, and foreign governments. Mentioned: Cambridge University press is offering a 20% discount here (until October) Susan's NBN interview with Richard Kreitner on Break It Up: Secession, Division, and The Secret History of America's Imperfect Union Jonathan A. Rodden's Why Cities Lose: The Deep Roots of the Urban-Rural Political Divide (Basic Books 2019) Hendrik Hertzberg's review of Robert A. Dahl's How Democratic Is the American Constitution (Yale) Shelby County v. Holder, the Supreme Court case that overturned the Voting Rights Act of 1965's pre-clearance requirement for historically discriminating districts Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/political-science

Since American president Donald Trump was elected to a second term, it is common to hear citizens, journalists, and public officials distinguish between the laws and leaders of their states and the national government. Those who oppose Trump's policies with regard to reproductive rights, gun violence, LGBTQ+, education, police, and voting often present state constitutions, courts, laws, culture, and leaders as a bulwark against Trump's autocratic rule.  But Professor Stephen H. Legomsky sees it differently. His new book, Reimagining the American Union: The Case for Abolishing State Government (Cambridge University Press 2025) argues that – if we care about democracy – we should imagine an America without state government. No longer a union of arbitrarily constructed states, the country would become a union of one American people. Reimagining the American Union understands state government as the root cause of the gravest threats to American democracy. While some of those threats are baked into the Constitution, the book argues that others are the product of state legislatures abusing their powers through gerrymanders, voter suppression, and other less-publicized manipulations that often target African-Americans and other minority voters. Reimagining the American Union interrogates how having national, state and local legislative bodies, taxation, bureaucracy, and regulation wastes taxpayer money and burdens the citizenry. After assessing the supposed benefits of state government, Professor Legomsky argues for a new, unitary American republic with only national and local governments. Stephen H. Legomsky is the John S. Lehmann University Professor Emeritus at the Washington University School of Law. Professor Legomsky has published scholarly books on immigration and refugee law, courts, and constitutional law. He served in the Obama Administration as Chief Counsel of U.S. Citizenship and Immigration Services and later as Senior Counselor to Secretary of Homeland Security Jeh Johnson. He was a member of President-Elect Biden's transition team, has testified often before Congress, and has worked with state, local, UN, and foreign governments. Mentioned: Cambridge University press is offering a 20% discount here (until October) Susan's NBN interview with Richard Kreitner on Break It Up: Secession, Division, and The Secret History of America's Imperfect Union Jonathan A. Rodden's Why Cities Lose: The Deep Roots of the Urban-Rural Political Divide (Basic Books 2019) Hendrik Hertzberg's review of Robert A. Dahl's How Democratic Is the American Constitution (Yale) Shelby County v. Holder, the Supreme Court case that overturned the Voting Rights Act of 1965's pre-clearance requirement for historically discriminating districts Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-studies

Since American president Donald Trump was elected to a second term, it is common to hear citizens, journalists, and public officials distinguish between the laws and leaders of their states and the national government. Those who oppose Trump's policies with regard to reproductive rights, gun violence, LGBTQ+, education, police, and voting often present state constitutions, courts, laws, culture, and leaders as a bulwark against Trump's autocratic rule.  But Professor Stephen H. Legomsky sees it differently. His new book, Reimagining the American Union: The Case for Abolishing State Government (Cambridge University Press 2025) argues that – if we care about democracy – we should imagine an America without state government. No longer a union of arbitrarily constructed states, the country would become a union of one American people. Reimagining the American Union understands state government as the root cause of the gravest threats to American democracy. While some of those threats are baked into the Constitution, the book argues that others are the product of state legislatures abusing their powers through gerrymanders, voter suppression, and other less-publicized manipulations that often target African-Americans and other minority voters. Reimagining the American Union interrogates how having national, state and local legislative bodies, taxation, bureaucracy, and regulation wastes taxpayer money and burdens the citizenry. After assessing the supposed benefits of state government, Professor Legomsky argues for a new, unitary American republic with only national and local governments. Stephen H. Legomsky is the John S. Lehmann University Professor Emeritus at the Washington University School of Law. Professor Legomsky has published scholarly books on immigration and refugee law, courts, and constitutional law. He served in the Obama Administration as Chief Counsel of U.S. Citizenship and Immigration Services and later as Senior Counselor to Secretary of Homeland Security Jeh Johnson. He was a member of President-Elect Biden's transition team, has testified often before Congress, and has worked with state, local, UN, and foreign governments. Mentioned: Cambridge University press is offering a 20% discount here (until October) Susan's NBN interview with Richard Kreitner on Break It Up: Secession, Division, and The Secret History of America's Imperfect Union Jonathan A. Rodden's Why Cities Lose: The Deep Roots of the Urban-Rural Political Divide (Basic Books 2019) Hendrik Hertzberg's review of Robert A. Dahl's How Democratic Is the American Constitution (Yale) Shelby County v. Holder, the Supreme Court case that overturned the Voting Rights Act of 1965's pre-clearance requirement for historically discriminating districts Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/politics-and-polemics

Since American president Donald Trump was elected to a second term, it is common to hear citizens, journalists, and public officials distinguish between the laws and leaders of their states and the national government. Those who oppose Trump's policies with regard to reproductive rights, gun violence, LGBTQ+, education, police, and voting often present state constitutions, courts, laws, culture, and leaders as a bulwark against Trump's autocratic rule.  But Professor Stephen H. Legomsky sees it differently. His new book, Reimagining the American Union: The Case for Abolishing State Government (Cambridge University Press 2025) argues that – if we care about democracy – we should imagine an America without state government. No longer a union of arbitrarily constructed states, the country would become a union of one American people. Reimagining the American Union understands state government as the root cause of the gravest threats to American democracy. While some of those threats are baked into the Constitution, the book argues that others are the product of state legislatures abusing their powers through gerrymanders, voter suppression, and other less-publicized manipulations that often target African-Americans and other minority voters. Reimagining the American Union interrogates how having national, state and local legislative bodies, taxation, bureaucracy, and regulation wastes taxpayer money and burdens the citizenry. After assessing the supposed benefits of state government, Professor Legomsky argues for a new, unitary American republic with only national and local governments. Stephen H. Legomsky is the John S. Lehmann University Professor Emeritus at the Washington University School of Law. Professor Legomsky has published scholarly books on immigration and refugee law, courts, and constitutional law. He served in the Obama Administration as Chief Counsel of U.S. Citizenship and Immigration Services and later as Senior Counselor to Secretary of Homeland Security Jeh Johnson. He was a member of President-Elect Biden's transition team, has testified often before Congress, and has worked with state, local, UN, and foreign governments. Mentioned: Cambridge University press is offering a 20% discount here (until October) Susan's NBN interview with Richard Kreitner on Break It Up: Secession, Division, and The Secret History of America's Imperfect Union Jonathan A. Rodden's Why Cities Lose: The Deep Roots of the Urban-Rural Political Divide (Basic Books 2019) Hendrik Hertzberg's review of Robert A. Dahl's How Democratic Is the American Constitution (Yale) Shelby County v. Holder, the Supreme Court case that overturned the Voting Rights Act of 1965's pre-clearance requirement for historically discriminating districts Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/law

Since American president Donald Trump was elected to a second term, it is common to hear citizens, journalists, and public officials distinguish between the laws and leaders of their states and the national government. Those who oppose Trump's policies with regard to reproductive rights, gun violence, LGBTQ+, education, police, and voting often present state constitutions, courts, laws, culture, and leaders as a bulwark against Trump's autocratic rule.  But Professor Stephen H. Legomsky sees it differently. His new book, Reimagining the American Union: The Case for Abolishing State Government (Cambridge University Press 2025) argues that – if we care about democracy – we should imagine an America without state government. No longer a union of arbitrarily constructed states, the country would become a union of one American people. Reimagining the American Union understands state government as the root cause of the gravest threats to American democracy. While some of those threats are baked into the Constitution, the book argues that others are the product of state legislatures abusing their powers through gerrymanders, voter suppression, and other less-publicized manipulations that often target African-Americans and other minority voters. Reimagining the American Union interrogates how having national, state and local legislative bodies, taxation, bureaucracy, and regulation wastes taxpayer money and burdens the citizenry. After assessing the supposed benefits of state government, Professor Legomsky argues for a new, unitary American republic with only national and local governments. Stephen H. Legomsky is the John S. Lehmann University Professor Emeritus at the Washington University School of Law. Professor Legomsky has published scholarly books on immigration and refugee law, courts, and constitutional law. He served in the Obama Administration as Chief Counsel of U.S. Citizenship and Immigration Services and later as Senior Counselor to Secretary of Homeland Security Jeh Johnson. He was a member of President-Elect Biden's transition team, has testified often before Congress, and has worked with state, local, UN, and foreign governments. Mentioned: Cambridge University press is offering a 20% discount here (until October) Susan's NBN interview with Richard Kreitner on Break It Up: Secession, Division, and The Secret History of America's Imperfect Union Jonathan A. Rodden's Why Cities Lose: The Deep Roots of the Urban-Rural Political Divide (Basic Books 2019) Hendrik Hertzberg's review of Robert A. Dahl's How Democratic Is the American Constitution (Yale) Shelby County v. Holder, the Supreme Court case that overturned the Voting Rights Act of 1965's pre-clearance requirement for historically discriminating districts Learn more about your ad choices. Visit megaphone.fm/adchoices

Since American president Donald Trump was elected to a second term, it is common to hear citizens, journalists, and public officials distinguish between the laws and leaders of their states and the national government. Those who oppose Trump's policies with regard to reproductive rights, gun violence, LGBTQ+, education, police, and voting often present state constitutions, courts, laws, culture, and leaders as a bulwark against Trump's autocratic rule.  But Professor Stephen H. Legomsky sees it differently. His new book, Reimagining the American Union: The Case for Abolishing State Government (Cambridge University Press 2025) argues that – if we care about democracy – we should imagine an America without state government. No longer a union of arbitrarily constructed states, the country would become a union of one American people. Reimagining the American Union understands state government as the root cause of the gravest threats to American democracy. While some of those threats are baked into the Constitution, the book argues that others are the product of state legislatures abusing their powers through gerrymanders, voter suppression, and other less-publicized manipulations that often target African-Americans and other minority voters. Reimagining the American Union interrogates how having national, state and local legislative bodies, taxation, bureaucracy, and regulation wastes taxpayer money and burdens the citizenry. After assessing the supposed benefits of state government, Professor Legomsky argues for a new, unitary American republic with only national and local governments. Stephen H. Legomsky is the John S. Lehmann University Professor Emeritus at the Washington University School of Law. Professor Legomsky has published scholarly books on immigration and refugee law, courts, and constitutional law. He served in the Obama Administration as Chief Counsel of U.S. Citizenship and Immigration Services and later as Senior Counselor to Secretary of Homeland Security Jeh Johnson. He was a member of President-Elect Biden's transition team, has testified often before Congress, and has worked with state, local, UN, and foreign governments. Mentioned: Cambridge University press is offering a 20% discount here (until October) Susan's NBN interview with Richard Kreitner on Break It Up: Secession, Division, and The Secret History of America's Imperfect Union Jonathan A. Rodden's Why Cities Lose: The Deep Roots of the Urban-Rural Political Divide (Basic Books 2019) Hendrik Hertzberg's review of Robert A. Dahl's How Democratic Is the American Constitution (Yale) Shelby County v. Holder, the Supreme Court case that overturned the Voting Rights Act of 1965's pre-clearance requirement for historically discriminating districts

This week on Breaking Battlegrounds, Congressman Mike Simpson of Idaho joins the show for a wide-ranging conversation that begins with his shocking discovery of the scale of missing and murdered Indigenous women—over 6,000 annually—and how Congress is finally taking action on justice and jurisdictional reform. He also breaks down the future of nuclear power, America's path to energy independence, and the urgent need to end our reliance on hostile nations for critical minerals and pharmaceuticals. Then, Newsweek's Josh Hammer returns to discuss his new book Israel and Civilization, where he argues that Israel—and the Jewish people—are the West's first line of defense against rising global threats. He also tackles the disturbing surge of anti-Semitism on college campuses, exposes the failures of higher education, and calls for revoking tax-exempt status for elite universities like Harvard. Don't miss Kiley's Corner, where she dives into the chilling mystery of 11 dead women found in New England over the last 60 days—is it the work of a serial killer or 11 separate psychopaths? Tune in now!www.breakingbattlegrounds.voteTwitter: www.twitter.com/Breaking_BattleFacebook: www.facebook.com/breakingbattlegroundsInstagram: www.instagram.com/breakingbattlegroundsLinkedIn: www.linkedin.com/company/breakingbattlegroundsTruth Social: https://truthsocial.com/@breakingbattlegroundsShow sponsors:Invest Yrefy - investyrefy.com4Freedom MobileExperience true freedom with 4Freedom Mobile, the exclusive provider offering nationwide coverage on all three major US networks (Verizon, AT&T, and T-Mobile) with just one SIM card. Our service not only connects you but also shields you from data collection by network operators, social media platforms, government agencies, and more.Use code ‘Battleground' to get your first month for $9 and save $10 a month every month after.Learn more at: 4FreedomMobile.comDot VoteWith a .VOTE website, you ensure your political campaign stands out among the competition while simplifying how you reach voters.Learn more at: dotvote.voteAbout our guest:An Idaho native, Mike Simpson was born in Burley and raised in Blackfoot. Mike graduated from Utah State University and earned his DMD from Washington University School of Dental Medicine in St. Louis, Missouri. After graduation, Mike joined his father and uncle at the Simpson Family Dental Practice in Blackfoot before serving in the Blackfoot City Council and State Legislature.Mike's political career began in 1980, when he was elected to the Blackfoot City Council. In 1984, he was elected to the Idaho Legislature where he served until 1998, the last six years serving as Speaker. Mike is currently serving his fourteenth term in the House of Representatives for Idaho's Second Congressional District.Mike serves as Chairman of the House Interior and Environment Subcommittee on Appropriations. His position gives him the unique opportunity to fight for Idaho's priorities and ensure Idahoans' hard-earned tax dollars come back to Idaho instead of going to states like New York or California.Mike also serves on the House Energy and Water Development Subcommittee and the Labor, Health and Human Services, Education Subcommittee on Appropriations. The committees Mike serves on have jurisdiction over funding for several agencies and programs critical to Idaho, including the Department of Energy, the Department of the Interior, the Forest Service, the National Parks Service, the National Endowment for the Arts, the Smithsonian Institute, and the Department of Labor.Mike and his wife Kathy have been married for 50 years and have called Idaho home all their lives. The two enjoy spending time with their poodle, Charley, and enjoying Idaho's beautiful scenery.-Josh Hammer is a friend of the show and the senior editor-at-large at Newsweek. He's the host of The Josh Hammer Show and the author of a new book, Israel and Civilization: The Fate of the Jewish Nation and the Destiny of the West, which recently reached as high as No. 3 on all of Amazon. You can follow him on X @josh_hammer. Get full access to Breaking Battlegrounds at breakingbattlegrounds.substack.com/subscribe

The topic of belonging and why it is so crucial to a healthy and high-functioning work environment within academic medicine is explored this week on the Faculty Factory Podcast with our esteemed return guest, Rakhee K. Bhayani, MD. Dr. Bhayani first joined our program in April 2022 for an episode covering career changes/pivots, identifying your purpose, and stepping outside of your comfort zone. You can revisit that discussion here: https://facultyfactory.org/rakhee-bhayani. She serves as Professor of Medicine and is the Vice Chair for Advancing Women's Careers in the Division of General Medicine and Geriatrics in the Department of Medicine at Washington University School of Medicine in St. Louis. "If we come to work and we have to specifically hide a part of who we are, that's mental energy and a tax that we're taking away from the work that we're doing,” she said. We welcome her back with open arms this week for an important and timely conversation on belonging's role in academic medicine and workplace culture. "Our goal is to help others feel comfortable and have that sense of safety, allowing them to bring their whole selves to work. This way, they can focus their energy on their work rather than expending mental energy on censoring parts of themselves to feel valued,” she added. Keep The Conversation Going Are you new to our show? Here are some similar Faculty Factory Podcasts to explore: Building a Sense of Belonging: A Faculty Factory Reunion with Heather Brod Identity Integration and Bringing Our Best Selves to Work with Jennifer Best, MD You can also find the full back catalog of the Faculty Factory Podcast here.  For feedback, questions, comments, and more information on how you can join the Faculty Factory as a guest, please visit our contact us homepage.

Traditional career development frameworks often overlook the importance of well-being. This podcast episode emphasizes why wellness is essential to building a sustainable and fulfilling career. Host Kyle Enfield, MD, FCCM, is joined by Jennifer Duncan, MD, and Raquel Cabral, PhD, CPH, to explore how team members and leaders can integrate personal values, connection, and purpose into career decision-making. Dr. Duncan, director of wellness for graduate medical education (GME), and Dr. Cabral, a staff psychologist for GME, both at Washington University School of Medicine, share insights from their work supporting trainees' personal and professional growth. Together, they explore the nuanced meaning of well-being—not as constant happiness, but as a sense of satisfaction and alignment with a person's values, even amid challenges. The conversation highlights the importance of helping team members identify and live by their personal values as a foundation for career satisfaction. Dr. Cabral distinguishes between goals and values, underscoring that, while goals can be achieved or not, values guide how a person shows up in all aspects of life. She outlines how residents and other early-career professionals can uncover values by reflecting on meaningful or difficult work experiences. These reflections can then guide decisions about clinical rotations, job searches, and leadership opportunities. Dr. Duncan emphasizes how small but intentional adjustments—such as carving out just 20% of one's time for personally meaningful work—can protect against burnout. Both guests discuss the critical role leaders play in supporting well-being, from understanding each team members' values to fostering a strong sense of community. They refer to The Burnout Challenge (Maslach C, Leiter MP. Harvard University Press. 2024), which outlines six workplace drivers of burnout, including mismatches in values. Finally, the episode highlights the work of the Mayo Clinic's Colleagues Meeting to Promote and Sustain Satisfaction (COMPASS) Groups. The COMPASS randomized clinical trial (West CP, et al. Mayo Clin Proc. 2021;96:2606-2614) evaluated a small group established to promote well-being. The group was provided discussion topics without trained facilitators. Protected time was not provided but meal expenses were compensated. This model showed positive outcomes in reducing burnout and strengthening collegial connections. This episode is part of SCCM's Leadership, Empowerment, and Development (LEAD) series and offers actionable insights for anyone invested in building healthier, value-aligned medical careers.

Jeffrey Magee, MD, PhD, Washington University School of Medicine, St. Louis, MO Recorded on April 3, 2025 Jeffrey Magee, MD, PhD Elizabeth H. and James S. McDonnell III Professor of Pediatrics Director, McDonnell Pediatric Cancer Center Division of Pediatric Hematology and Oncology Washington University School of Medicine St. Louis, MO In this episode, we sit down with Dr. Jeffrey Magee from the McDonald Pediatric Cancer Center at the Washington University School of Medicine in St. Louis to discuss the evolving landscape of pediatric blood cancers. Reflecting on his work, Dr. Magee shares, “One of the things I really love about the job is that it operates right at the interface between the science and the professional practice of medicine.” He examines groundbreaking advances bringing new hope to children and their families, from novel therapies and CAR T-cell therapy to the crucial role of clinical trials. Dr. Magee also speaks candidly about the challenges of delivering difficult news and shares compassionate strategies for supporting families through their toughest moments. Join us for this insightful and informative conversation on the future of pediatric blood cancer care today!

  Lisa Gitelson - The Fresh Air Fund: Because a Summer Can Last a Lifetime. This is episode 756 of Teaching Learning Leading K12, an audio podcast. Lisa Gitelson is the CEO of The Fresh Air Fund. Each year the nearly 148-year-old nonprofit invites about 3,000 low-income New York City-based children ages 8-18 to spend the summer swimming, rowing, hiking, and stargazing in Fresh Air Fund camps. Throughout Lisa's career in public service, as an attorney and child welfare advocate, she has been dedicated to addressing the needs of underserved youth.  Prior to joining The Fund, she was Assistant Executive Director/Legal Counsel for The New York Society for the Prevention of Cruelty to Children (NYSPCC). She is also an Adjunct Professor at Silberman School of Social Work, Hunter College, CUNY, where she teaches the Policy & Practice of Child Welfare.  As Assistant Executive Director/Legal Counsel for NYSPCC, Lisa identified legislation and other public policy issues that impacted the organization's work and developed an advocacy agenda to move public policy efforts forward.  Previously, she served as Associate Executive Director, Downstate, at the Council of Family and Child Caring Agencies (COFCCA) where she was responsible for bringing private foster care, juvenile justice, residential care and prevention services agencies together to coordinate advocacy efforts for the child welfare and juvenile justice systems. In this role, Lisa represented COFCCA member agencies in discussions with the Administration for Children's Services, the New York City Council and the New York State Office of Children and Family Services.    Prior to COFCCA, Lisa was the Director of Foster Care and Adoption Services at Sheltering Arms Children and Family Services. She began her career as an attorney representing foster care agencies before serving in multiple leadership and supervisory roles at the New York City Administration for Children's Services, Family Court Legal Services. Lisa is a graduate of Colgate University and has a JD from Washington University School of Law. Our focus today is The Fresh Air Fund. Awesome talk! So much to learn! Please share. Before you go... You could help support this podcast by Buying Me A Coffee. Not really buying me something to drink but clicking on the link on my home page at https://stevenmiletto.com for Buy Me a Coffee or by going to this link Buy Me a Coffee. This would allow you to donate to help the show address the costs associated with producing the podcast from upgrading gear to the fees associated with producing the show. That would be cool. Thanks for thinking about it.  Hey, I've got another favor...could you share the podcast with one of your friends, colleagues, and family members? Hmmm? What do you think? Thank you! You are AWESOME! Connect & Learn More: https://freshair.org/ https://x.com/FreshAirFund https://www.instagram.com/thefreshairfund/?hl=en https://www.facebook.com/freshairfund LGitelson@freshair.org Length - 32:10

Morgan had not turned 45 yet, so she hadn't received a screening colonoscopy for colorectal cancer. But when she noticed blood in her stool at age 41, she did exactly what she should have and sought medical evaluation. After months of missteps became years of dismissive care, she realized it was time for a second opinion at Siteman Cancer Center. With the help of WashU Medicine radiation oncologist Hyun Kim, MD, co-director of the Young-Onset Colorectal Cancer Program, Morgan was given a treatment plan that provided the care she needed. In this episode, we discuss her persistence and dedication to getting herself the best care for her young-onset colorectal cancer diagnosis.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/colorectal/young-onset-colorectal-cancer-program/ https://siteman.wustl.edu/treatment/cancer-types/colorectal/prevention-and-screening/  https://siteman.wustl.edu/doctor/kim-hyun/ https://getscreenednow.com/colon-cancer/ https://getscreenednow.com/insurance/  

In the second edition of a special podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about the best practices for incorporating recently approved bispecific antibodies into cancer care. This discussion focused on clinical trial results, administration protocols, and adverse effect (AE) management strategies related to the use of tarlatamab-dlle (Imdelltra) for patients with small cell lung cancer (SCLC). Morgensztern is a professor of Medicine and the clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital. The conversation opened with Morgensztern highlighting tarlatamab's mechanism of action as an agent that targets DLL3. He then reviewed prior efficacy data that the therapy demonstrated in the phase 1 DeLLphi-300 trial (NCT03319940) and the phase 2 DeLLphi-301 trial (NCT05060016). Of note, the FDA approved tarlatamab as the first available T-cell engager immunotherapy for patients with extensive-stage SCLC who have progressed on prior platinum-containing chemotherapy in May 2024 based on data from the DeLLphi-301 trial. Additionally, Flanagan detailed strategies for monitoring and mitigating the most common AEs associated with tarlatamab in this patient population, which include cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome. Mann then outlined considerations for properly dosing and administering the agent, highlighting factors that clinicians should keep in mind when continuing treatment in an inpatient or outpatient setting. The group also spoke about clinical decision-making related to patients who have brain metastases, which included processes for adjusting the dose of tarlatamab and sequencing the bispecific agent with radiotherapy. Reference FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. News release. FDA. May 16, 2024. Accessed March 14, 2025. https://tinyurl.com/48k34rw5

Host: Ece Cali Daylan, Assistant Professor of Medicine, Division of Oncology at Washington University School of Medicine Guest: Saadettin Kilickap Guest: Ozden Altundag

In this episode of Admissions Straight Talk, Dr. Beth Piraino, Associate Dean of Admissions at the University of Pittsburgh School of Medicine (UPSOM), explores the school's innovative Three Rivers Curriculum, emphasizing small-group learning, early clinical exposure, and the integration of "Streams" (special interest areas) and Threads" (core competencies like leadership and clinical reasoning). Dr. Piraino also discusses the role of secondary essays in evaluating applicants and explores why teamwork, resilience, and cultural awareness are important in the admissions process. She goes on to  highlight a common mistake applicants make in the application process.Relevant Links:University of Pittsburgh School of Medicine Are You Ready to Apply Med School QuizRelated Shows:Inside Geisinger Med School Admissions with Dr. Michelle SchmudeAccepted: Your Guide to CU School of Medicine Get Accepted to Washington University School of MedicineDeep Dive into Duke Medical: An Interview with Dr. Linton YeeGet Accepted to Loyola Stritch Medical SchoolFollow UsYouTubeFacebookLinkedInContact Uswww.accepted.comsupport@accepted.com+1 (310) 815-9553

Black pediatric patients believed to have neurological conditions are falling through the cracks. A new study finds that just half of Black patients completed the necessary genetic tests for diagnosis and treatment. St. Louis Public Radio's Marissanne Lewis-Thompson spoke with Dr. Christina Gurnett, co-author of the Washington University School of Medicine study highlighting the barriers Black families face accessing care.

>>Want more information like this? Sign up for Modern Endocrine's⁠⁠⁠⁠⁠⁠⁠⁠ ⁠newsletter⁠⁠⁠⁠⁠⁠⁠⁠

Interview with Harry A. Quigley, MD, author of Shedding LiGHT on Selective Laser Trabeculoplasty, and guest Michael A. Kass, MD, Washington University School of Medicine in St Louis. Hosted by Neil M. Bressler, MD. Related Content: Shedding LiGHT on Selective Laser Trabeculoplasty

Interview with Harry A. Quigley, MD, author of Shedding LiGHT on Selective Laser Trabeculoplasty, and guest Michael A. Kass, MD, Washington University School of Medicine in St Louis. Hosted by Neil M. Bressler, MD. Related Content: Shedding LiGHT on Selective Laser Trabeculoplasty

The show you are about to experience serves twofold. First and foremost, this conversation design elicits knowledge from an experienced individual or expert. It is modeled on conversational theory and utilizes a protagonist, me, to crack into deeper knowledge by a vigorous discussion.  Pioneer Knowledge Services has become adept in this practice and offers it as a service. Think of all those super smart people retiring.  It is the best way to secure and transfer knowledge. The other piece of what this show provides is a self-help guide leading a community group. It will aid anyone as an example to leading communities. Stan Garfield, a true leader in the field of knowledge management, has been a friend to Pioneer Knowledge Services® for many years. Find him on LinkedIn and learn more about the Systems Integration and Knowledge Management (SIKM) Leaders Community. Stan Garfield is a knowledge management author, speaker, and community leader based in Northville, Michigan. This is his 30th year in the field of knowledge management.. Stan spent 8 years at Deloitte leading communities and enterprise social networking. Prior to that, he spent 25 years at HP, Compaq, and Digital Equipment Corporation. Stan launched Digital's first knowledge management program in 1996, helped develop the corporate KM strategy for Compaq, and led the Worldwide Consulting & Integration Knowledge Management Program for HP. He also worked for PricewaterhouseCoopers, St. Louis University School of Medicine, and Washington University School of Medicine. Stan holds a BS in Applied Mathematics and Computer Science from Washington University in St. Louis.  He leads the SIKM Leaders Community, February 2025, it has 1,264 members globally. The community's main activities are Online threaded discussions – discussions on the field of knowledge management, questions and answers, and links to job postings Monthly calls – presentations by members and invited speakers Stan is invited to present at numerous conferences, including KMWorld and the APQC KM Conference. He has published over 1,000 articles on leadership, innovation, knowledge management, communities of practice, enterprise social networks, and social media. He is the author of the Profiles in Knowledge series featuring knowledge management thought leaders. Books Implementing a Successful KM Program (2007) Successful Knowledge Leadership: Principles and Practice (2013), Chapter 5: The Modern Knowledge Leader: A Results-Oriented Approach Gaining Buy-in for KM (2014), Chapter 2: Obtaining support for KM: The ten commitments Measuring the ROI of Knowledge Management (2016), 2nd Edition, Chapter 7: The case against ROI for knowledge management Proven Practices for Promoting a Knowledge Management Program (2017) Knowledge Management Matters: Words of Wisdom from Leading Practitioners (2018), Chapter 6: Communities Manifesto Handbook of Community Management: A Guide to Leading Communities of Practice (2020) The Five Cs of KM (2022) Knowledge Nuggets: 100 KM Infographics (2023) Profiles in Knowledge: 120 Thought Leaders in Knowledge Management (2024) Content Knowledge Management Site: http://sites.google.com/site/stangarfield/ LinkedIn Profile: http://www.linkedin.com/in/stangarfield/ Twitter Feed: http://twitter.com/stangarfield

In the first edition of a special 3-part podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about best practices for implementing recently approved bispecific antibodies into cancer care. Their initial discussion focused on the clinical trial results, administration protocols, and toxicity management strategies related to the use of amivantamab-vmjw (Rybrevant) for patients with EGFR-mutated non–small cell lung cancer (NSCLC). Morgensztern is a professor of Medicine and clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University in St. Louis. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine in St. Louis and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital. Morgensztern began by giving an overview of amivantamab's mechanism of action and highlighting supporting data for the agent when administered alone or in combination with other agents.  The FDA initially approved amivantamab monotherapy for patients with EGFR exon 20 insertion–mutant NSCLC in May 2021 based on data from the phase 1 CHRYSALIS trial (NCT02609776). Furthermore, the agency approved amivantamab/chemotherapy as frontline treatment for patients with NSCLC harboring EGFR exon 20 insertion mutations in March 2024 based on data from the phase 3 PAPILLON trial (NCT04538664). Findings from the phase 3 MARIPOSA trial (NCT04487080) also supported the FDA approval of amivantamab plus lazertinib (Lazcluze) for those with EGFR-mutant NSCLC in August 2024. Additionally, Mann reviewed key dosing considerations as patients receive amivantamab via intravenous infusion. She detailed the use of premedication such as diphenhydramine (Benadryl) to supplement amivantamab while monitoring for toxicities during the initial infusion period, which may necessitate additional dosing adjustments. Flanagan added to the conversation surrounding infusion-related reactions by describing strategies for mitigating the risk of venous thromboembolism, cutaneous toxicities, and other adverse effects. References 1. RYBREVANTTM (amivantamab-vmjw) receives FDA approval as the first targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. News release. The Janssen Pharmaceutical Companies of Johnson & Johnson. May 21, 2021. Accessed January 29, 2025. https://tinyurl.com/3d8wtu4m 2. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. News release. FDA. March 1, 2024. Accessed January 29, 2025. https://tinyurl.com/msw4u5yk 3. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. News release. Johnson & Johnson. August 20, 2024. Accessed January 29, 2025. https://tinyurl.com/yxc8u8t4

Overview: Explore the evolving landscape of Alzheimer's diagnosis, where blood tests are emerging as a critical tool in clinical practice. In this episode, we'll examine how these tests add value to traditional diagnostic methods and the latest research validating their accuracy. Join us to discover the potential of blood tests in transforming Alzheimer's diagnosis.   Guest: Suzanne E. Schindler, MD, PhD, Associate Professor of Neurology, Washington University School of Medicine   For more information, please visit: https://www.pri-med.com/clinical-resources/podcast/ceoi-alzheimers-diagnostics-pt-1 

To celebrate our 50th episode we are honored to welcome Dr. Robert Bucelli on the show. He is a leading expert in neuromuscular neurology and a dedicated advocate for advancing treatments for neuromuscular disorders.  In this episode, Dr. Bucelli shares his wealth of knowledge on neuromuscular neurology, exploring topics such as: What neuromuscular neurology entails and who is affected. The role of genetics in diagnosing and treating neuromuscular disorders. Common symptoms, risk factors, and diagnostic approaches. How therapies like physical and occupational therapy play a role in management. Lifestyle modifications, including diet and exercise, to minimize risk. The latest advancements in research and treatment, including ASO therapy. Strategies for coping with the challenges of living with neuromuscular conditions. Dr. Bucelli has been a practicing neurologist at the ALS Clinic since 2011. He is an Associate Professor of Neurology at the Washington University School of Medicine in St. Louis where he serves as the Site Principal Investigator on several clinical studies relating to ALS.   After graduating summa cum laude from Canisius College in Buffalo, New York with a degree in biology, Dr. Bucelli went on to receive his medical degree and PhD from the State University of New York at Buffalo as part of the Medical Scientist Training Program. He then completed an internship in internal medicine and postgraduate residency in neurology at Barnes-Jewish Hospital and the Washington University School of Medicine, followed by a postgraduate Clinical Fellowship Training Program in the Department of Neurology's Neuromuscular Section, also at Barnes-Jewish and Washington University. He is also a graduate of the Washington University and Barnes-Jewish Hospital Academic Medical Leadership Program for Physicians and Scientists.   Dr. Bucelli is expert in diagnosing and treating neuromuscular disorders including amyotrophic lateral sclerosis. He also reads and interprets muscle and nerve biopsies to aid in the diagnostic evaluations of patients seen at Washington University and many additional outside institutions. Dr. Bucelli's clinical expertise guides exemplary multidisciplinary ALS care in the neuromuscular clinic. His skill in delivering drugs to the fluid surrounding the spinal cord has enabled Dr. Bucelli's and Washington University's leadership in trials using to turn off the production of harmful genes that cause ALS.   Dr. Bucelli has received numerous awards for excellence in teaching and clinical work at Washington University. He is a five-time recipient of the Eliasson Award for Teaching Excellence and has authored over 40 peer-reviewed manuscripts. He is a frequently invited guest lecturer and presenter at regional and national conferences.   Stay tuned for the next new episode of “It Happened To Me” in the New Year on January 6th, 2025! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com.   

In this heartfelt episode of The Patient From Hell, host Samira Daswani talks to Jill Massey, a pharmacist and pharma industry veteran whose path through cancer has been both personal and professional. Jill shares her experiences as a caregiver for her sister, mother, and husband—all cancer patients—before becoming a patient herself. They discuss the emotional and practical challenges of navigating caregiving, the complexities of the healthcare system, and how Jill's unique perspective as both a medical professional and a patient shaped her approach to advocacy, treatment decisions, and resilience. Key Highlights: 1. A Personal and Professional Journey: Jill reflects on how her family's battles with cancer shaped her career in the pharmaceutical industry, blending personal empathy with professional expertise. 2. Balancing Roles and Emotions: From sibling to spouse to patient, Jill shares the unique emotional dynamics of each role and the coping mechanisms she developed. 3. Empowerment Through Knowledge: Jill emphasizes the importance of patient education, advocating for personalized care, and the evolving role of pharmaceutical companies in supporting patient-centric care. About our guest: Jill Massey, PharmD, MBA, BCMAS is Vice President, Global Medical Strategy and Operations (GMSO) for Gilead Medical Affairs.  In this role, Jill oversees the Patient-focused Implementation Science team, Medical Strategy and Planning, Insights, Data & Analytics and Digital Innovation, Medical Excellence, Medical Affairs Technology, and Scientific Communications including global publications, medical information, medical external affairs and education, and library and information services.   Jill joined Gilead Sciences from Immunomedics where she led the Medical Affairs, Safety and Pharmacovigilance organizations.  Prior to that, she led Medical Affairs at Janssen, The Medicines Company and Melinta Therapeutics as well as the Melinta Global Antimicrobial Resistance Program. She began her career in the pharmaceutical industry at Bristol-Myers Squibb Company.  Previous to her industry roles, Jill was clinical faculty at the Saint Louis College of Pharmacy, Jewish Hospital and the Program on Aging at Washington University School of Medicine.  Jill is a member of the Board of Directors for the Morris County Chamber of Commerce and serves on the Life Sciences Council Steering Committee.  She is a member of the National Advisory Committee for the Robert A. Winn Diversity in Clinical Trials Award Program, a member of the Accreditation Council of Medical Affairs Executive Leadership Board and a member of the Seton Hall University Transformative Leadership Advisory Board.   Jill earned her Doctor of Pharmacy degree from the University of Nebraska Medical Center and her MBA from Drexel University LeBow College of Business. She completed a residency at Mercer University School of Pharmacy and Emory University. She is Board Certified by ACMA.   Jill loves running, baking and spending time with her two kids, Maddie and Alex, and her loved ones, sometimes including her two dogs and cat. Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only.  This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Karen Joynt Maddox is an associate professor of medicine at Washington University School of Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. S.A. Shashikumar, A.M. Ryan, and K.E. Joynt Maddox. Medicare's New Mandatory Bundled-Payment Program — Are We Ready for TEAM? N Engl J Med 2024;391:2065-2067.

On November 22, the United Nations General Assembly's legal arm, the Sixth Committee, adopted a resolution paving the way for negotiations on a first-ever treaty on preventing and punishing crimes against humanity. The resolution comes after years of impasse and after Russia and a handful of other countries dropped amendments that could have derailed the process at the last-minute. Crimes against humanity are those committed as part of a large-scale attack on civilians and include acts such as murder, rape, imprisonment, enforced disappearances, sexual slavery, torture and deportation. To be considered a crime against humanity, a violation doesn't necessarily have to occur during an active war. And while crimes against humanity are covered by the International Criminal Court, nearly 70 countries are not members of the Court, which creates a gap in fully prosecuting these crimes in countries from Sudan to Syria to Myanmar. What can we expect next as States prepare for negotiations, and how might a future crimes against humanity treaty close the impunity gap?  Joining the show to unpack the developments on the crimes against humanity treaty are Akila Radhakrishnan and Leila Sadat.  Akila is an international human rights lawyer and gender-justice expert, who currently serves as the Strategic Legal Advisor for Gender Justice for the Atlantic Council's Strategic Litigation Project. Leila is the James Carr Professor of International Criminal Law and longtime Director of the Whitney R. Harris World Law Institute at Washington University School of Law. Show Notes: Akila Radhakrishnan (@akila_rad)Leila Nadya Sadat (@leilasadat1)Paras Shah (@pshah518) Just Security's Proposed Crimes Against Humanity Treaty coverageJust Security's International Law coverageJust Security's International Criminal Court coverageMusic: “Broken” by David Bullard from Uppbeat: https://uppbeat.io/t/david-bullard/broken (License code: OSC7K3LCPSGXISVI)

“I went to law school at age 49 at Washington University School of Law, which is an Ivy League-level law school. I graduated with a 4.0, the highest GPA in my class. When people ask me how I did that while doing all this other stuff at the same time, I like to joke and say ‘I cheated.' At Orientation they told us we should spend four hours per class per week preparing for lectures. I spent eight hours preparing. Most people say, that's not cheating. Yes, but nobody does it. If you want to be the smartest person in the room, you have to be the most prepared person in the room. See, there's nothing extra-ordinary about me. I was a below average student in high school. I just start with the conviction that failure is not an option and I cannot be outworked. Then I move on to: ‘I'm going to out prepare everyone.' You see, the harder you work, the luckier you get.” Stephen Nalley is the owner and Managing Partner of Black Briar Advisors, which is a Small Business Administration and Veteran's Affairs Certified-Disabled Service-Connected Veteran-Owned Company. He has owned and operated over 200 hotels across the United States and has managed over $2 billion in Hotel & Resort Assets. He is the author of "Relentless Pursuit," where he describes the secret to success as knowing what you want and having a compelling reason why and the discipline to sacrifice what we want right now for what we really want later.

I'm thrilled today to welcome new friend, Albertina Antognini and old (by which I mean long-time) friend, Susan Appleton. Albertina Antognini is the James E. Rogers Professor of Law at the University of Arizona where she teaches Family Law, Property, Trusts & Estates, and a seminar surveying different legal regimes that shape the contemporary American family. Professor Antognini's work examines the ways that legal rules actively regulate, and in the process define, families. Her research is centrally preoccupied with considering how categories that may appear “natural” are in fact products of law, with the aim of opening them up to a more rigorous critique.Susan Appleton is the Lemma Barkeloo & Phoebe Couzins Professor of Law at Washington University School of Law. She is a nationally known expert in family law and feminist legal theory. Her research, scholarship, and teaching address reproductive justice, parentage, gender, sexualities, and public assistance for families. They join us today to discuss their recent article, Sexual Agreements, published in the Wash. U. Law Review. UVA Law 3L, Laura Habib, co-hosts this episode. Further ReadingAntognini and Appleton, Sexual Agreements, 99 Wash. U. L. Rev. 1807 (2022)Antognini bio https://law.arizona.edu/person/albertina-antogniniAntognini, Nonmarital Contracts, 73 Stan. L. Rev. 67 (2021)Antognini, Nonmarital Coverture, 99 B.U. L. Rev. 2139 (2019)Appleton bio https://law.wustl.edu/faculty-staff-directory/profile/susan-frelich-appleton/Appleton, Sex Positive Feminism's Values in Search of the Law of Pleasure, in The Oxford Handbook of Feminism and Law in the United States (Deborah L. Brake, Martha Chamallas, & Verna Williams eds., 2023).Appleton, Families Under Construction: Parentage, Adoption, and Assisted Reproduction (with D. Kelly Weisberg) (2021).Krawiec bio https://www.law.virginia.edu/faculty/profile/kdk4q/1181653Krawiec, Gametes: Commodification and The Fertility Industry, in Routledge Handbook of Commodification, Routledge, 278–289 (1 ed. 2023).Krawiec, Markets, repugnance, and externalities, Journal of Institutional Economics 1–12 (2022).Krawiec, No Money Allowed, 2022 University of Chicago Legal Forum 221–240 (2022).

It used to be that surgery for medically refractory epilepsy was big, open and invasive, a treatment of last resort. The landscape has changed in recent decades, with more and more minimally invasive surgical approaches being developed. So what does this mean for the average patient with medically refractory epilepsy? Our guest today is Dr. Jon Willie, Associate Professor, Department of Neurological Surgery, Washington University School of Medicine in St. Louis. He speaks with Dr. Ionnis Karakis, Epileptologist and Adjunct Professor of Neurology at Emory University, about the new landscape of epilepsy surgery. Series 6, Episode 2 Featuring: Guest: Jon T. Willie, MD, PhD, FAANS, Associate Professor, Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri Interviewer: Ioannis Karakis, MD, PhD, MSc., Epileptologist and Adjunct Professor of Neurology at Emory University Disclosures: Dr. Karakis disclosed that he is a consultant for USB, GSK, Ceribell, and Epitel. Dr. Willie disclosed Consulting for Clearpoint, Inc, AiM Medical Robotics, Inc., and Fortec Medical, Inc.; Contracted Research with Abbott, Inc., Neurona, Inc., and Neuropace, Inc.; and Honoraria from Medtronic, Inc. 

Listen to ASCO's Journal of Clinical Oncology Art of Oncology poem, "Episteme” by Dr. Michael Slade, who is a medical oncologist at Washington University School of Medicine. The poem is followed by an interview with Slade and host Dr. Lidia Schapira. Dr Slade highlights the tension between what is known and unknown and what spoken and unspoken as physicians try to care for our patients without destroying their ability to live with their disease. TRANSCRIPT Narrator: Episteme, by Michael J. Slade, MD, MSCI  I know you know, must know. The tides have woken you night after night after night, borrowed blood flowing in and now out, unaided by your dwindling marrow. You must know your story is read and written in a perfecta tense. You must know the end somewhere deep in your empty bones.   Still, you speak of summers, of fish caught or lost beneath the calm surface of a distant lake. “There's nothing to do in December,” you say, skin pale in the cool light leaking from the door. It's late now, deep in the evening and my knees ache as I nod and wonder about a different world where you were not you and this was all decided months ago.   “Day by day,” I mutter and shuffle to my next door, leaving you alone to wait on the cataclysm, on that night when the blood of strangers runs wild and catches your breath, that night in the ICU, where they wait, tube in hand as you sweat and shake, where I still promise to care for you knowing, knowing you will never wake again. Dr. Lidia Schapira: Hello and welcome to JCO's Cancer Stories, the Art of Oncology, which features essays and personal reflections from authors exploring their experience in the field of oncology. I'm your host, Dr. Lidia Schapira. I'm a Professor of Medicine at Stanford University. Today we are joined by Dr. Michael Slade, a Medical Oncologist at Washington University School of Medicine. In this episode, we will be discussing his Art of Oncology poem, “Episteme.”  Our guest's disclosures will be linked in the transcript.  Mike, welcome to our podcast and thank you for joining us. Dr. Michael Slade: Thank you, Lidia. It's great to be here. Dr. Lidia Schapira: It's a pleasure to have you. Let's start by talking a little bit about your relationship to writing prose, poetry. Is this something that you've always done? Do you want to share with us a little bit about what it means to you and when you have time to write? Dr. Michael Slade: I'd say, I have absolutely no formal training as a poet or honestly in anything else, but this is something I've done since college. And especially starting in medical school, this was really a deliberate practice for me to try to find a way to unload some of the harder experiences that we can go through as medical providers. Dr. Lidia Schapira: It's interesting to hear you say that. Many of our authors have talked about using their writing as a way of processing emotionally difficult experiences and just very important meaningful experiences. But there's so much artistry in your work. I just wanted to ask you a little bit more about that. How do you find the relationship to not just the writing as a way of processing, but as art that you want to share and publish. I've seen that you've published poems, quite a few of them in the last year alone. Dr. Michael Slade: Yeah, I would say the publishing piece of this came very far down the road for me, that I've been writing for over a decade before I think I even submitted anything for publication. And for me, the ability to publish is more of a- Is a way of putting yourself out there and as a motivation to really re-examine what you've written and not just scrawl it on a piece of paper and sort of stick it back on a shelf somewhere, but to be able to go back to some of these experiences and really delve a little bit deeper, both with the language, but also what was the experience? Why was this meaningful? And often things that end up in print for me are things that I've been playing with for a number of years. It is just sort of an ability to go deeper there is the reason why I have published some of these works. Dr. Lidia Schapira: I am very interested in the theme of time and your use of pronouns. There's a lot of negotiating. What is yours and what is your patients'? I assume the “I” is the oncologist, right? In this particular case, since the readership of JCO are mostly clinical oncologists, it's sort of meant to be an affiliation with a reader. And there's a lot of “I,” but then there's a lot of mine. Can you talk a little bit about how you have chosen to address the patient directly and your colleagues directly and put yourself out there using first person as well? Dr. Michael Slade: I think certainly, as I wrote this, and I tend to write a lot as I come off of sort of tough stretches of clinical work, and as I wrote this, I think, I was trying to capture a little bit of the anguish that I think a lot of us feel as oncologists, especially around this question of what we know and what is knowledge for the oncologist. The reality is the things that we know sort of above the neck tend to be very statistical, that we say, “Oh, the chances of you responding,” “The chances of you surviving,” “The chances of you being cured,” it's very numbers based, but it's probabilistic. And when we talk to patients and often when we talk to ourselves, we really use this idea of knowing in a very different way, that we know that something's going to happen because of our past experience or because of what we're seeing right in front of us. I think that's something that I think a lot of oncologists probably identify with very closely is that what do we do when we feel like we know something in a way that's almost deeper than the academic way that we speak of knowing. Dr. Lidia Schapira: Let's talk about that. And that is, in fact, the title you chose for your poem. Why not just use the word knowledge? Tell us a little bit about that choice. Dr. Michael Slade” When we talked about knowing, both academically and my background before I came to medicine, as I trained in philosophy, we talked about epistemology or episteme. Often, we talk about knowing both in medicine and in sort of the wider philosophical discussions, we talk about it in this very abstract way that if you were to sit down with a patient and really try to unpack it, they're not going to have any idea. This isn't relevant to practical life in a lot of ways. They want to know, “Am I going to be cured?” “Am I going to have this side effect?” “Am I going to make it out of the hospital?” And the type of knowing that we do within science is not that type of knowing. It's all probabilistic. And to me, I think, trying to pull back a little bit, and by using the sort of Greek root, it sort of places this idea of knowledge at a remove that I think is useful. Dr. Lidia Schapira: Mike, I've often used the analogy that poetry is almost like abstract art sometimes, because it invites the reader to imagine things. So if we think of this poem sort of as art, can we walk through this together and take it from the top and see what we see or what these ideas trigger? You start directly by addressing the I know, you know, you must know. And then you present the case, if I got this right, of somebody with a dwindling marrow, that's an empty bone, so an inefficient marrow. And I assume, since you're a bone marrow transplanter, that means this patient had a disease that was incurable here, and you sort of insist that you must know. Tell me a little bit about that tension, that emotional tension that comes up for me as I read that, those opening lines where you're sort of insisting that you must know something that you're not sharing with me that you know. Dr. Michael Slade: I think for me, that's really trying to express the gap that can emerge between those of us who do this professionally and our patients who have to live through these experiences. And we can say, “I have seen this story play out so many times, and I know things are not going well. I know how this is going to end.” But for the patient, this is, obviously, every patient is an n-of-1 with their own experience, and they may have had family members with similar diseases, they may have had friends. They may join these really wonderful patient support groups where people can sort of talk about what the process of cancer treatment is. But for the patient, they are living through it day to day. And we may feel with our accumulated knowledge that it's very clear how things are going and that either their optimism or pessimism or sort of whatever the patient's base emotional reaction is to the clinical situation is fundamentally incorrect. It's like you have to put these pieces together in the way that I do. And the reality is that there is a huge gap that can emerge between us and our patients, and it can lead to frustration and anguish and a lot of negative emotions, I think, from clinicians that aren't aimed at the patient, but they're really aimed at the fact that we feel like we're not talking about the same situation. I think that's what that first piece of the poem is really trying to capture, is that anguish at that type of gap. Dr. Lidia Schapira: And you say it very clearly. You say, “You must know your story is read and written in the perfect tense.” It's almost like you're shouting it here, right? Dr. Michael Slade: But in sort of a weird, obscure way that if you tried to tell a patient sort of a grammatical metaphor for how poorly their hospitalization was going. Most patients, unless they're English literature professors, will look at you as sort of with this, “What are you talking about?” I think, again, it's that gap. It's this very academic, removed way that we often look at this, especially when we're trying to shield ourselves from this very human anguish of knowing that there's this real person in front of you who's not doing well and that you feel like you kind of know how the story is going to end. Dr. Lidia Schapira: Let's go a little deeper into that then. It's really about your feelings then here. It's your frustration. You want the patient to mirror back to you that they get how bad this is, and they can't because they are trapped in that body, in that situation. And as you just say, and then you say in the lines that follow, “they are coming up for air.” They're thinking of the summer and the fish that may be caught or not caught. They may know it somewhere, but they can't quite recite that back to you. And that leads the writer, the author, to voice this inner tension. Did I get that right? Dr. Michael Slade: I think that's exactly it. And sort of towards the end of that verse, there's also sort of this counterfactual that certainly different choices can always be made in the course of treatment. And especially for us clinicians when we're encountering a patient who interprets their disease a little bit differently than we do, and they say, “Oh, I feel fine. Why do I need chemo after surgery?” Or, “Oh, I feel fine. Why do I need a bone marrow transplant?” And sometimes people will make choices which makes their immediate life better, but we are always stuck in this sort of feeling of, “Oh, man. If only we had done things a little bit differently.” I acknowledge that we just can't align our views of the world, but still at the same time saying, “Well, I don't know, things would have been better if you'd listened to me. Maybe you made the right choice for you and your disease process.” So it's always that gap between what we know academically and what we sort of know below the neck. And then for patients, their experience is often very different from ours because they have to live through this. Dr. Lidia Schapira: I'm interested in the physician narrator experience here, and I was really impressed by the fact that you convey the tension on the emotional load. But the only thing that you write and communicate directly to the reader is the physical aching, when you say, “it's the evening and my knees ache,” and then you say “I shuffle,” suggesting that you're physically tired. I just wonder if you could talk a little bit more about that, the way that you have inserted the fatigue factor of the narrator here, but through the description of physical symptoms. Dr. Michael Slade: I think there's a little bit of blending there, because I think on the one hand, certainly this emotional anguish, mental anguish can certainly manifest as fatigue, and sometimes can be sort of a little bit of a metaphorical blend there. But I think the other thing that we often really struggle with as physicians and as other providers is how much are we letting ourselves get into the story that the patient is experiencing, but even the story that we're trying to objectively put together. And because, for example, we had a patient who tried a treatment and they had a rare side effect, a lot of us will admit, “Hey, I had a patient with a bad outcome when they got X,Y,Z.” Even if the data looks really good because of my own emotional processing or I do my best. And I know a lot of other physicians talk about this, but if you are tired, hungry, under or over caffeinated, having bad things going at home a lot of times for us, we worry about letting our personal lives bleed into our interactions with patients. And that's really challenging because I think we are at our best when we bring our humanness into the clinic room, into the hospital room. We also have to make sure that we're not saying, “Oh, am I just down because I'm tired, and that's why I think this patient's going to do poorly?” Or is it actually supported by the evidence in front of us? So I think the way that the narrator kind of moves in and out of this piece and how much they are a part of the story is a big piece of the poem. Dr. Lidia Schapira: It is a very big piece of the poem. And as I read some of the other poems you've written, I think that I was also impressed by this construction of the boundaries and the separateness between the patient and the physician narrator and how you negotiate that when you're waiting for a result, when you're waiting for time, when you say it's really the patient's story, but it's yours too. There's a fluidity about this perspective. Did I get that right? Dr. Michael Slade: I think that's an absolutely wonderful way to describe it. I think fluidity in particular is, yeah, that we think of things as very separate from each other and that I'm me and you're you and there's your family and there's the rest of the team. But all of this stuff, not to get too sort of hippie with it, but there's so much resonance when you're in these relationships that you have with patients. And especially in cancer care, we have very deep, often very prolonged and somewhat intense relationships with patients and their families as they go through this stuff. Boundaries can become blurred. And again, I think it's challenging because sometimes we are at our best when we blur those boundaries a little bit. But there's certainly- you can be pulled into a patient's story in a way that is not helpful for you long term, but even not helpful for the patient short term. And I think that's the challenge. And you're right. I spend a lot of my work sort of thinking about this. And a lot of my professional life is also thinking about this. Dr. Lidia Schapira: I would say it a little differently. And it's that you are co-constructing an ‘us' that is between you and they, or you and he or she, or however you see this. And that's the mind part. Others have talked about cases where there is a deep connection between physician and patient, where the physician is invited to be a co-editor of that patient narrative. I think there's a lot of richness in that. And I think that your work and your poetry certainly takes us right there.  And so with that, I want to take us to the end of the poem, which is terrifying.There's going to be, you use the word ‘cataclysmic', which means, this is an upheaval, something violent about to happen. And the way I interpret it is your patient is neutropenic and septic and shaking and rigoring and is getting transfused. And the “They,” which isn't you or your team, it's the ‘they' are waiting for it too and going into probably an intubation in the ICU. And then there's this promise that you won't abandon the patient while ‘they' are going to be doing these things. And we already know how this story is going to end. Is that what you are trying to convey? Dr. Michael Slade: It's funny because until you sort of read it out, I was like, I didn't realize how much I threw our ICU colleagues under the bus as part of this poem. So if any of you guys are listening, I have immense respect and value for what you do. But no, and this is sort of the big question that we run into with these patients and what's the right response when we feel like we can see the future and then we turn out to be correct. How do we not, I guess, insulate ourselves from that in a way that's not helpful for us and it's not helpful for the patient? And yeah, so that's sort of, as I said, you read the story sort of as it was laid down, but yeah. What do you do? What's the right response when you feel like you're getting to the end and that you feel like you've seen it coming for weeks? And I think that's really the challenge. And the poem sort of suggests an answer to that question. But I think everybody kind of has their own process that they have to go through. As you see, unfortunately, as an oncologist, case after case of folks that- cancer is tough and our treatments are getting better, but I'm a myeloma physician. I have cured zero patients so far. And that's hard at the end of the story. It's always hard. Dr. Lidia Schapira: It is hard. Can you tell us a little bit about your choice of language and why you keep repeating the ‘knowing' and then italicize it at the end, just to add another dimension of emphasis there? Dr. Michael Slade: As someone who loves language and has always been interested in it from a philosophical perspective, but literary perspective as well, there's really, really sharp limitations to what language can express. And we can unpack and define and redefine and suggest. But there's something- often, we in these situations, run up into a place where words are totally insufficient. And I feel like often what we end up doing and what I end up doing in writing but I think even in our interactions with people, we just sort of use the same words over and over again, hoping that somehow the meaning will morph mid-interaction and suddenly we'll have that connection with someone where they'll hear what we're trying to say. And for me, I kept coming back to this idea of knowing, knowing, knowing. The narrator's trying to express something that they just can't quite get their arms around. And I think the best and the closest I can get to in similar situations is something like this, is trying to write out these experiences in a way that kind of captures that feeling. I hope I at least captured a piece of it. Dr. Lidia Schapira: Certainly. I loved your writing and I think you did. Despite how difficult it is to talk about this and how difficult it must have been for you to live through it, there's a real gentleness about the way you take the reader through this. And it evolves. Really, it flows beautifully. So thank you for that. Dr. Michael Slade: I very much appreciate the writing. And I will say to the folks who read the original version of this poem, both in my personal life and then at JCO, this is not the original form the poem was in. So I think other people have layered in their experiences here. And again, I love to see this come out on the other end and say, this is more beautiful than what I started with. So I have a lot of gratitude to folks who have given me some pointers about how to improve this. Dr. Lidia Schapira: It's lovely to hear you say that. To end this, I would love to hear you tell me a little bit about comments, perhaps, that colleagues or even patients may have made based on work that you've published or what you hope that people will take away from this. Dr. Michael Slade: I had published maybe one poem back in medical school, and then I published something as a fellow. And I remember in our program, we have this big office and we basically all have cubicles, and we have sort of the computers all set up, and we're in and out, you know, seeing consults and everything else. And I had published something in JCO a few years ago, that was about indirectly the experience of trying to be on call and triage patients and all this. I had maybe three or four different fellows within the week that that was published, sort of stick their head over and be like, “I never read poetry, but I saw your name on this. So I flipped to the back of the JCO magazine and read it.” And that captured so many of the feelings that I've had this year in a way that I couldn't put on paper. Again, I've been writing stuff since college and most of it sits in a folder somewhere and it's never read by anybody. So the idea that it could go out into the world and could make people have that sort of sense of catharsis that I'm not alone in this. Somebody else has had this experience and had this feeling.  I've had that same experience with some of my very brilliant colleagues who paint or who participate in other sorts of artistic endeavors. And it's nice to know that there's a community of people out here. We're all just trying to navigate the same stuff. And if we can sort of help each other, if we can capture these experiences and retranslate them in a way that people can process their own, sometimes, grief. I think it's really wonderful. Dr. Lidia Schapira: Yes. To create a thoughtful community and accompany one another. Well, thank you for sharing your art and your wisdom and your knowing with us today, and please keep writing.  And for our listeners, until next time, thank you for listening to JCO's Cancer Stories, the Art of Oncology. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all of the ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Like, share and subscribe so you never miss an episode and leave a rating or review.   Guest Bio: Dr. Michael Slade is a Medical Oncologist at Washington University School of Medicine.

JONATHAN KANTER This episode was recorded on November 18, 2024,  the day when it was reported that Senior antitrust officials at the Justice Department plan to ask a judge to order Google to divest its Chrome web browser, Bloomberg reported citing anonymous sources. The department also intends to ask federal judge Amit Mehta, who declared Google's search engine a monopoly in August, to mandate actions concerning artificial intelligence and the Android mobile operating system. The enforcement actions are the product of the Justice Department's multiyear case against Google which sought to prove that the tech giant has a web search monopoly in the U.S. The Justice Department won its case  federal judge Amit Mehta ruled that Google broke antitrust laws in both online search and search text ads markets. The remedies are yet to be decided and will likely be fought in federal courts. Many parallels exist between this case and  US v Standard Oil in the early 20th century and US v Microsoft in the early 21st century. The remarkable person leading this effort which at its root goes to the heart of free markets, power and competition is Assistant Attorney General of the United States' Department of Justice Antitrust Division. He is deeply thoughtful and his mind is expansive, especially at the intersection of the law, free markets. Prior to this, Kanter worked as an antitrust attorney at the FTC and in private practice. AAG Kanter is considered a critic of “big tech” and DOJ has worked to block  a record number of mergers on antitrust  grounds. During his tenure, the DOJ won its first conviction in a criminal monopolization suit in four decades Jonathan has a very humble beginning in a working class neighborhood of Queens and  graduated from SUNY Albany and Washington University School of Law.  After graduating from law school, Kanter first worked as an antitrust lawyer at the FTC. He later worked in private practice, where he represented clients including Microsoft and Yelp as an  associate at Fried, Frank, Harris, Shriver & Jacobson. Kanter was later a partner at Cadwalader, Wickersham & Taft followed by  Paul, Weiss, Rifkind, Wharton & Garrison.  Two other notable cases he has led include an antitrust suit related to JetBlue's attempted acquisition of Spirit, and one against Ticketmaster's parent company Live Nation Entertainment. Upon filing the lawsuit, Kanter stated that "Live music should not be available only to those who can afford to pay the Ticketmaster tax". Much of his work, as was his confirmation by the United States Senate, has broad support across party lines, a rare thing in today's Washington.  RELATED LINKS NYT Article CNBC Segment Wikipedia Bloomberg Article Stanford Graduate School of Business Talk GENERAL INFO| TOP OF THE GAME: Official website: https://topofthegame-thepod.com/ RSS Feed: https://feed.podbean.com/topofthegame-thepod/feed.xml Hosting service show website: https://topofthegame-thepod.podbean.com/ Javier's LinkTree: https://linktr.ee/javiersaade  SUPPORT & CONNECT: LinkedIn: https://www.linkedin.com/showcase/96934564 Facebook: https://www.facebook.com/profile.php?id=61551086203755 Twitter: https://twitter.com/TOPOFGAMEpod Subscribe on Podbean: https://www.podbean.com/site/podcatcher/index/blog/vLKLE1SKjf6G Email us: info@topofthegame-thepod.com   THANK YOU FOR LISTENING – AVAILABLE ON ALL MAJOR PLATFORMS

In this thought-provoking episode of Parallax, Host, Dr Ankur Kalra engages in an illuminating conversation with Dr Karen Joynt Maddox, a distinguished cardiologist and health policy researcher at Washington University School of Medicine in St. Louis. Together, they navigate the complex intersection of cardiovascular medicine, health economics, and public health policy. Dr Joynt Maddox shares her unique journey into health economics research, offering valuable insights for cardiologists considering this vital career path. The discussion delves deep into the need for enhanced collaboration between clinicians and policymakers, emphasizing how physicians' frontline experiences can inform more effective healthcare policies. In examining the growing presence of private equity in cardiology practices, Dr Joynt Maddox provides nuanced insights into this transformative trend. Through thoughtful analysis, she explores how this financial model shapes healthcare delivery, innovation, and patient outcomes. The conversation extends to broader economic challenges in cardiovascular medicine, particularly the intricate balance between fostering medical innovation and ensuring accessible, affordable care for patients. Drawing from her extensive research experience, Dr Joynt Maddox emphasizes the role of social determinants in cardiovascular health outcomes. The episode concludes with a compelling discussion on integrating public health principles into medical education, offering a vision for a more holistic approach to cardiovascular care.

It can be scary, difficult and complicated, but it doesn't always have to be. … Lung cancer is the No. 1 cause of cancer deaths — not just because of its aggressive nature, but because it's also frequently diagnosed late. But why? Hear from two survivors about their experiences and the importance of screening, which can catch lung cancer earlier, when it's more treatable.    “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/cancer-types/lung-cancer/ https://siteman.wustl.edu/treatment/cancer-types/lung-cancer/treatments/ https://siteman.wustl.edu/lung-cancer-screening/ https://siteman.wustl.edu/prevention/smoking-cessation-program/ https://siteman.wustl.edu/prevention/ydr/ https://www.smokingpackyears.com/ https://smokefree.gov/ https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/saved-by-the-scan

Discover insights into the challenging landscape of Cushing syndrome, where adrenal variations require careful diagnostic and therapeutic strategies. In this podcast, Sina Jasim, MD, MPH, Editor-in-Chief of the AACE Clinical Reports (ACCR) and Associate Professor of Medicine at Washington University School of Medicine, leads a compelling discussion on two unique cases featured in the ACCR article, Histopathologic Differences Between Adrenocorticotropic Hormone–Dependent and Adrenocorticotropic Hormone–Independent Adrenal Hyperplasia Causing Cushing Syndrome. Authors, Amir H Hamrahian, MD, Endocrinologist, Associate Professor, and Medical Director of the Comprehensive Adrenal Center at Johns Hopkins University School of Medicine, and Ezra Baraban, MD, Assistant Professor of Pathology at Johns Hopkins University School of Medicine, explain the diagnostic challenges for each case, the decision-making process between medical and surgical approaches, and the critical role of pathology in guiding clinical care. Read the full case report in ACCR at https://www.aaceclinicalcasereports.com/article/S2376-0605(22)00066-9/fulltext.

Dr. Jonathan (Jony) Kipnis is a BJC Investigator and the Alan A. and Edith L. Wolff Distinguished Professor of Pathology and Immunology at Washington University School of Medicine in St. Louis. He is also Professor of Neurology, Neuroscience, and Neurosurgery and Director of the Brain Immunology and Glia Center there. Jony is a neuroimmunologist. He works at the intersection of the immune system and the nervous system. The brain controls immune system activity, and the immune system affects brain function. The two work together to ensure our survival and well-being. Jony's research is improving our understanding of how they interact when we're healthy and in cases of nervous system damage or disease. When he's not working, Jony loves to read a good book, enjoy a nice glass of wine, cook, and eat delicious food. He particularly has a passion for grilling. He completed his BSc in Biology at Tel Aviv University, and he received his MSc in Neurobiology and PhD in Neuroimmunology from the Weizmann Institute of Science in Israel. Jony worked on the faculty at the University of Virginia for over a decade before joining the faculty at Washington University in St. Louis. He has received numerous awards and honors, including an NIH/NIA MERIT Award, the NIH Director's Pioneer Award, the Harrison Foundation Distinguished Teaching Professorship in Neuroscience, a Gutenberg Research College fellowship from the Johannes Gutenberg University of Mainz, and the Distinguished Research Career Development Award from the University of Virginia. He is also a Member of the National Academy of Medicine. In this interview, Jony shares more about his life and science.

After minor blurred vision prompted Ellen to get an eye exam, she was surprised to learn she had a mass in the middle of her brain near the nerve connected to her left eye. A referral to Siteman quickly led to the diagnosis of a brain tumor. Fortunately, it was noncancerous and had a surgical solution. Washington University neurosurgeon Albert Kim, MD, PhD, director of The Brain Tumor Center at Siteman, explains minimally invasive surgery techniques and other new treatments that speed recovery for benign tumor patients like Ellen and others facing brain cancer.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/thisiscancer/ https://siteman.wustl.edu/ https://siteman.wustl.edu/neuro-oncology/ https://siteman.wustl.edu/treatment/cancer-types/brain-tumor-center/

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HERE---Episode Overview: What does it take to transform healthcare from reactive to proactive while making it more accessible and affordable? Our next guest, Dr. Tom Maddox, is pioneering this evolution as Vice President of Digital Products and Innovation at BJC HealthCare and Washington University School of Medicine. With decades of experience as a practicing cardiologist and health services researcher, Tom brings unique insights into healthcare's digital future. While together, Tom shares his passion for leading both the Healthcare Innovation Lab and BJC Digital team, and how he and his team are transforming care delivery through predictive analytics, virtual nursing solutions, and digital patient engagement tools. Join us to explore how Tom is leveraging technology to create personalized, frictionless healthcare experiences while empowering caregivers with modern tools and workflows. Let's go!Episode Highlights:Reframe innovation as "a new idea that when implemented creates value"- focused on solving real healthcare problems, not just creating new technologyDeploy virtual care for clinician-to-clinician support, using experienced virtual nurses to mentor younger staff while managing patient careRevolutionize scheduling by using data analytics to identify and proactively reach out to at-risk patients who need immediate attentionEnhance healthcare workers' capabilities through technology rather than replace them, addressing healthcare's persisting 90% labor ratioTarget healthcare's core challenges by making care more accessible, less reactive, and more affordable through technological innovationAbout our Guest: Dr. Maddox is a senior health system executive overseeing digital health and innovation programs, a practicing cardiologist, a health services researcher, and a national leader in cardiology professional societies.Dr. Maddox is the Vice President, Digital Products and Innovation at BJC HealthCare and Washington University School of Medicine in St. Louis. In this role, he provides strategic oversight and direction of both the BJC/WUSM Healthcare Innovation Lab and the BJC Digital Products team.The Healthcare Innovation Lab catalyzes care delivery innovation through research and development at BJC HealthCare and its academic partner, Washington University School of Medicine. To date, the Lab has developed innovations in predictive analytics, digital point-of-care tools, and remote patient monitoring. The BJC Digital team is responsible for delivering the digital vision of BJC HealthCare to support its enterprise goal of customer-centricity. The digital team builds and deploys digital products - such as online portals, apps, and wearables – that can help our patients and care teams receive and deliver optimal healthcare experiences and outcomes. Current products enable clinician search, online scheduling, primary care visit preparation, nurse scheduling, and virtual nursing.In his faculty role, Dr. Maddox is a Professor of Medicine (Cardiology) at Washington University School of Medicine. He is a practicing non-invasive cardiologist, a trained epidemiologist, and an accomplished health services researcher. Dr. Maddox is well known for his contributions to digital transformation, healthcare delivery innovation, learning healthcare systems, and health services research in cardiac quality and safety. He is a member of the National Academy of Medicine's Digital Health Action Collaborative and...

When Byron was diagnosed with prostate cancer, he underwent surgery to have it removed. But when doctors noticed his PSA levels were still rising following the procedure, they offered him access to an open clinical trial. Byron shares his experiences from the 6-month trial along with his Washington University radiation oncologist Lannis Hall, MD. From upsides, to side effects, Byron and Dr. Hall use his story to illustrate the benefits of clinical trials, and how each trial's research furthers our understanding and potential cures for cancer.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/research/learn-about-clinical-trials/ https://siteman.wustl.edu/treatment/clinical-trials/ https://siteman.wustl.edu/treatment/clinical-trials/?path=gu-bladder-kidney-prostate-testicular-prostate https://siteman.wustl.edu/treatment/cancer-types/prostate/treatments/radiation-therapy-for-prostate-cancer/ https://siteman.wustl.edu/treatment/cancer-types/prostate/treatments/ https://siteman.wustl.edu/about/dei/

Former NHL player Kelly Chase is known as one of the toughest guys to wear a St. Louis Blues jersey, racking up more than 2,000 penalty minutes in his career. But when his Washington University oncologist Dr. Ramzi Abboud diagnosed him with acute myeloid leukemia in 2023, Chase learned he was facing an opponent different than anything he challenged on the ice – one needing more than brute force.    Listen as Chase and Dr. Abboud share the intense and taxing treatment plan needed to overcome Chase's rare cancer and what Chase learned about himself during his time at Siteman Cancer Center.     “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/thisiscancer/ https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/cancer-types/leukemia/ https://stlbluesalumni.com/Events/Puck-Cancer-Charity-Game  

Ingrid Skop, M.D., FACOG, is Vice President and Director of Medical Affairs for Charlotte Lozier Institute, leveraging more than 30 years' experience as a practicing obstetrician-gynecologist to support research and policies that respect the dignity of every human life.Dr. Skop received her Bachelor of Science in physiology from Oklahoma State University and her medical doctorate from Washington University School of Medicine. She completed her residency in obstetrics and gynecology at the University of Texas Health Science Center at San Antonio. Dr. Skop is a Fellow of the American College of Obstetricians and Gynecologists, where she uses science and statistics to counter pro-abortion agendas, and is a lifetime member of the American Association of Pro-Life Obstetricians and Gynecologists.Prior to joining Charlotte Lozier Institute, Dr. Skop served for over 25 years in private practice in San Antonio, where she delivered more than 5,000 babies and personally cared for many women who had been harmed, physically and emotionally, from complications due to abortion. She has served as board member and medical director for pregnancy resource centers in San Antonio, Austin, and Houston. Dr. Skop's research on maternal mortality, abortion, and women's health has been published in multiple peer-reviewed journals. Additionally, she has provided expert testimony at both the state and federal levels on legislation related to abortion, including standing firm against prominent pro-abortion politicians who choose not to follow the science regarding fetal heartbeat and development.Dr. Skop is married to a physician and is the proud mother of two sons and a daughter. https://lozierinstitute.org/  Become a supporter of this podcast: https://www.spreaker.com/podcast/i-am-refocused-radio--2671113/support.

This week, we're presenting stories from scientists who faced unusually difficult paths to science. We all know it's hard work to become a scientist. But for some folks, even getting to that point where you can pursue your science education can seem like an impossible dream. Part 1: When Evelyn Valdez-Ward discovers that she's undocumented, she fears her dreams of becoming a scientist are over.  Part 2: Samuel Achilefu's experiences growing up during the Nigerian Civil War inspire his passion for science.  Evelyn Valdez-Ward is an undocumented, Latina, scientist and PhD student at the University of California, Irvine. For her thesis, she studies the impact of California's drought on the ways that plants and their soil microbes (fungi and bacteria in the soil) communicate and interact with one another. In addition to doing research, she's extremely passionate about advocating for undocumented students in STEM. She recently published her story "I'm an undocumented scientist fighting for my Dream" in Science, and was invited to speak at the March for Science rally in DC to advocate for Dreamers in STEM. She has been awarded a UCI's Dynamic Womxn's Award for Outstanding Social Justice Activist, and the Svetlana Bersahdsky Graduate Student Award for her lobbying and advocacy efforts. She plans to continue lobbying and fighting for her undocumented community after graduating, and work in science policy, where she can continue to advocate for both science and minorities in STEM. Originally from Nigeria, Samuel Achilefu is the Michel M. Ter-Pogossian Professor of Radiology at Washington University School of Medicine. He also holds joint appointments as a Professor in Medicine, Biochemistry & Molecular Biophysics, and Biomedical Engineering and serves as the Chief of the Optical Radiology Laboratory (ORL), Director of the Molecular Imaging Center, Director of the Center for Multiple Myeloma Nanotherapy, and a co-leader of the Oncologic Imaging Program of the Siteman Cancer Center. His lab harnesses the power of light to develop methods for understanding, diagnosing and treating human diseases and is made up of biologists, chemists, engineers, medical scientists and physicists. He enjoys biking, playing tennis, and travelling. Samuel lives with his wife and they have two college-aged children. Learn more about your ad choices. Visit megaphone.fm/adchoices